DoW Reconstructive Transplant, Concept Award | HT942526RTRPCA

FY26 DoD Reconstructive Transplant Research Program (RTRP) Concept Award FAQs

What is the FY26 RTRP Concept Award?

The FY26 Department of Defense Reconstructive Transplant Research Program (RTRP) Concept Award is a discretionary grant opportunity (Funding Opportunity Number: HT942526RTRPCA) administered by the Defense Health Agency Contracting Activity. It supports early-stage, high-risk, high-reward research intended to explore genuinely new concepts or untested theories in reconstructive transplantation.

What is the main purpose of this award?

The purpose is to let researchers test bold, conceptually novel ideas that could shift how the field approaches major challenges in reconstructive transplantation. The program is not intended to fund incremental extensions of existing research lines.

What kind of research is this opportunity trying to fund?

This mechanism is aimed at concept exploration: innovative, foundational, mechanistic, or other non-clinical-trial research that can generate interpretable outcomes and help validate or invalidate a new idea. The emphasis is on opening new directions for the field rather than polishing or scaling prior work.

How important is innovation for competitiveness?

Innovation is a defining expectation. Competitive projects are expected to introduce a new paradigm, challenge current assumptions, or tackle a longstanding problem from an unconventional angle. Applications that mainly build on already published findings with only modest advances are explicitly described as not being a good fit.

Does the proposed work need to align to specific program priorities?

Yes. Proposed work must align with at least one of the FY26 RTRP Focus Areas. Applicants are expected to clearly map their aims to one or more focus areas as defined in the full program materials.

What does “relevance” mean in the context of this award?

Relevance means there should be a clear connection between the proposed concept and a meaningful need within reconstructive transplantation. Reviewers will look for a strong explanation of why the problem matters and how the proposed idea could lead to progress if it proves viable.

Are applicants allowed to include preliminary data?

No. A specific rule for this award is that applicants are not allowed to present preliminary data. Even so, the application still needs to persuade reviewers that the project can produce interpretable results within the proposed scope.

If preliminary data are not allowed, how can an application demonstrate feasibility?

The application should rely on a strong scientific rationale, a well-thought-out approach, and a realistic plan for generating clear, analyzable outcomes that can validate or invalidate the concept. The focus is on whether the project can generate informative findings, not on prior proof-of-concept results.

Are clinical trials allowed under this funding mechanism?

No. Clinical trials are not supported under this mechanism. Projects should remain in preclinical, foundational, mechanistic, or other non-trial research activities that match the award’s intent of concept exploration rather than clinical testing.

What if my project would require a human clinical trial to achieve its aims?

If achieving the aims would require designing or executing a human clinical trial, the project would not be appropriate for this award mechanism as described in the opportunity summary.

Who is eligible to apply?

The opportunity lists an unrestricted eligible applicant pool. In addition, eligibility extends to investigators at or above the postdoctoral fellow level, which means postdoctoral researchers and more senior investigators may apply.

Does the program encourage early-career investigators?

Yes. Early-career investigators are explicitly encouraged to apply. The inclusion of postdoctoral fellows (and above) signals the program’s intent to help seed transformative ideas while also supporting the next generation of reconstructive transplantation researchers.

How many awards are expected to be made?

The opportunity indicates an expected three awards.

What is the application deadline?

The original application closing date listed is September 16, 2026.

What funding instrument is used for this opportunity?

The opportunity uses a grant funding instrument.

Which government body administers this grant opportunity?

It is administered by the Defense Health Agency Contracting Activity within the Department of Defense.

What is the Funding Opportunity Number (FON)?

The Funding Opportunity Number is HT942526RTRPCA.

What program/category does this fall under?

The listing categorizes the opportunity under Science and Technology and other Research and Development and references CFDA 12.420.

How much funding is available per award?

The posted listing includes an “Award Ceiling” field, but the excerpt provided does not include a specific dollar amount. Applicants would need to consult the full announcement for funding limits, allowable costs, and budget rules.

Where can applicants find details like the award ceiling, allowable costs, and budget restrictions?

Those details are not included in the provided excerpt. The summary notes that applicants should consult the full announcement for the funding limits, allowable costs, and other budget rules.

Is this award intended to extend existing projects?

No. The program intent is to avoid small or incremental extensions of existing work. The award is designed to test creative new concepts that could change how the field thinks about key challenges.

What kind of outcome is the program trying to achieve through this mechanism?

The program is trying to stimulate conceptually novel research that can open new directions in reconstructive transplant science by generating interpretable results that help decide whether a new idea is viable.